- 1 Title: Multiplex Target-Redundant RT-LAMP for Robust Detection of SARS-CoV-2 Using Fluorescent
- 2 Universal Displacement Probes
- 3 **Authors:** Enos C Kline<sup>1</sup>, Nuttada Panpradist<sup>1,2</sup>, Ian T Hull<sup>1</sup>, Qin Wang<sup>1</sup>, Amy K Oreskovic<sup>1</sup>, Peter D
- 4 Han<sup>3,4</sup>, Lea M Starita<sup>3,4</sup>, Barry R Lutz<sup>1,4</sup>

# 5 Affiliations

- 6 1 Department of Bioengineering, University of Washington, Seattle, WA, USA
- 7 2 Global Health for Women Adolescents and Children, School of Public Health, University of
- 8 Washington, Seattle, WA, USA
- 9 3 Department of Genome Sciences, University of Washington, Seattle, WA, USA
- 10 4 Brotman Baty Institute for Precision Medicine, Seattle, WA, USA

#### 11

- 12 \* Correspondence: B. R. L. (blutz@uw.edu)
- 13 3720 15<sup>th</sup> Ave NE, Campus Box 355061, Seattle, Washington, United States 98195
- 14

# 15 Abstract

16 The increasing prevalence of variant lineages during the COVID-19 pandemic has the potential to 17 disrupt molecular diagnostics due to mismatches between primers and variant templates. Point-of-care molecular diagnostics, which often lack the complete functionality of their high throughput laboratory 18 19 counterparts, are particularly susceptible to this type of disruption, which can result in false negative 20 results. To address this challenge, we have developed a robust Loop Mediated Isothermal Amplification 21 assay with single tube multiplexed multi-target redundancy and an internal amplification control. A 22 convenient and cost-effective target specific fluorescence detection system allows amplifications to be 23 grouped by signal using adaptable probes for pooled reporting of SARS-COV-2 target amplifications or 24 differentiation of the Internal Amplification Control. Over the course of the pandemic, primer coverage of 25 viral lineages by the three redundant sub-assays has varied from assay to assay as they have diverged 26 from the Wuhan-Hu-1 isolate sequence, but aggregate coverage has remained high for all variant 27 sequences analyzed, with a minimum of 97.4% (Variant of Interest: Eta). In three instances (Delta, 28 Gamma, Eta), a high frequency mismatch with one of the three sub-assays was observed, but overall 29 coverage remained high due to multi-target redundancy. When challenged with extracted human samples 30 the multiplexed assay showed 100% sensitivity for samples containing greater than 30 copies of viral 31 RNA per reaction, and 100% specificity. These results are further evidence that conventional laboratory 32 methodologies can be leveraged at the point-of-care for robust performance and diagnostic stability over 33 time.

# 34 Introduction

The COVID-19 pandemic is an unprecedented crisis in the modern era, spreading across the planet in a matter of months, infecting and killing millions, while disrupting the lives of billions (1). An essential element of the response strategies to COVID-19 is diagnostic testing, which informs clinical intervention, quarantine, and epidemiological monitoring (2). Nucleic acid amplification tests (NAATs)

remain the most accurate approach for diagnosis of infectious diseases including SARS-CoV-2 infection.
 However, RNA viruses like SARS-CoV-2 have a high mutational rate, which can result in elevated levels

- 41 of sequence diversity accumulating as they propagate. This is a critical obstacle for NAATS because
- 42 mismatches between the primer oligonucleotides and the template sequences can impair an assay and
- 43 produce false negative results. As transmission has progressed, SARS-CoV-2 has diversified in distinct
- 44 lineages, each with signature mutations throughout the genome (3). The emergence of this genetic
- 45 diversity has rendered some NAATs susceptible to false negative results, causing these tests to be altered
- 46 or withdrawn by the U.S. FDA (4). This challenge posed by mutation for NAATs is not limited to SARS-
- 47 CoV-2; similar phenomena have been observed for other human pathogens (5, 6).

48 Laboratory testing strategies to lessen this risk include redundant testing with alternative 49 methods, diagnostic panels with multiple target regions (7), and/or primer sets with degenerate bases to 50 account for known genetic variability (8). While degenerate primers are accessible and inexpensive, they 51 are often limited by assay design constraints and do not account for unknown or novel mutations. Repeat 52 and multiple testing is an effective strategy, but requires additional resources, labor, and complexity of 53 design or implementation. These considerations are manageable in contemporary diagnostic laboratories 54 but can be prohibitive in lower resource settings. Nearly all laboratory assays for SARS-CoV-2 use 55 redundant targets to mitigate mutations and an internal control to account for sample processing or

56 interference.

57 A critical aspect of the Center for Disease Control and Prevention's (CDC) Strategy for Global 58 Response to COVID-19 (2020-2023) is augmenting our current ability to rapidly identify COVID-19 59 infections so that the chain of transmission can be disrupted. Essential to this effort is the development of 60 diagnostics that can be performed at the point-of-care (POC); that minimize the time to result (TTR) of the test and are deployable in otherwise underserved populations. These settings are inherently "low 61 62 resource," and necessitate diagnostic methods with simplified chemistry, hardware, and limited sample processing relative to the standard of practice for molecular diagnostics, polymerase chain reaction 63 64 (PCR). Advancements in isothermal nucleic acid amplification technologies over the past three decades 65 largely satisfy these constraints while still providing high sensitivity. This has led to a boom in isothermal 66 amplification technologies and NAATs based on them (9). Despite their advantages, there are some areas 67 where the isothermal NAATs are lacking when compared to PCR. Single-pot multiplexing has been 68 infrequently demonstrated despite being a prerequisite for internal amplification control (IAC) systems 69 and useful for multiple target redundancy (10-12) In this work we look to contribute to this capability as 70 it relates to Loop Mediated Isothermal Amplification (LAMP) for the detection of SARS-COV-2.

71 Herein we describe a multiplexed reverse transcriptase LAMP (mRT-LAMP) combining three 72 assays, each targeting a unique region of the nucleocapsid (NC) gene, and an IAC assay to validate 73 diagnostic viability with a negative result. To accomplish this, we have designed a universal target 74 specific fluorescence probe system. In this method, engineered adapter sequences are incorporated into 75 the LAMP amplicons which then serve as a template for detection by displacement probes. The resulting 76 assay chemistry is sensitive, specific, and durable while simplifying the development process. We 77 evaluate the limit of detection, cross-reactivity with other organisms, and reactivity with extracted RNA 78 from patients infected SARS-CoV-2.

# 79 Materials and Methods

# 80 **Preparation of TFpol polymerase**

81 Plasmid preparation and protein expression and purification were performed as previously described (13).

#### 82 Primer and IAC design

- 83 Three sets of LAMP primers (**Table 1**) targeting different regions of the SARS-CoV-2
- 84 nucleocapsid phosphoprotein were designed manually using the primer design feature of Geneious 8.1.9
- 85 (14) against the SARS-CoV-2 reference sequence (GenBank accession number: NC\_045512). IDT
- 86 OligoAnalyzer (15) and NUPACK (16) were used to evaluate designs in silico. Each target design
- 87 consists of the six conventional LAMP primers: F3, B3, FIP, BIP; LF, and LR (17). The IAC was
- 88 designed using a composite primer technique (18) for LAMP. IAC template sequence was derived from
- target region "NC1" by substituting the target loop primer binding sites with engineered sequences. One
- 90 of the engineered IAC loop sites was used as an IAC loop primer while the other was omitted, so that the
- 91 IAC assay uses a single loop primer (LFc mut in **Fig. 1B**). For each primer set a loop primer was
- 92 modified by the addition of an engineered probe adapter sequence at its 5' end, with all targets sharing a
- common adapter and the control assay using a second unique adapter sequence. Primer oligonucleotides
- 94 were sourced from Integrated DNA Technologies (Coralville, Iowa, USA).
- 95 Table 1: Primer, Probe, and control sequences for the SARS-CoV-2 mRT-LAMP. For Primers and
- probes, F2/B2 sequences are underlined, non-template linker sequences are italicized, and adapter
- 97 sequences are shown in bold.

SARS-CoV-2 NC1 Primers	Sequence
NC1 FIP	CCACTGCGTTCTCCATTC <i>TTTTCCCCCGCATTACGTTTGGT</i>
NC1 BIP	GCGATCAAAACAACGTCGG <i>TTAT<u>TGCCATGTTGAGTGAGAGCG</u></i>
NC1 LF	TGGTTACTGCCAGTTGAATCT
NC1 LB + Target adapter	<b>ACCAACACCTCACATCACACATAATA</b> GGTTTACCCAATAATACTGCGTCTTG
NC1 F3	TGGACCCCAAAATCAGCG
NC1 B3	ATCTGGACTGCTATTGGTGTTA
SARS-CoV-2 NC2 Primers	Sequence
NC2 FIP	CAGCTTCTGGCCCAGTTCCT <u>GTGGTGGTGACGGTAAAATG</u>
NC2 BIP	CTTCCCTATGGTGCTAACAAAG <i>T</i> <u>CCAATGTGATCTTTTGGTGTATTCA</u>
NC2 LF	GTAGTAGAAATACCATCTTGGACT
NC2 LB + Target adapter	ACCAACACCTCACATCACACATAATAATATGGGTTGCAACTGAGGGAG
NC2 F3	CTACTACCGAAGAGCTACCAG
NC2 B3	GCAGCATTGTTAGCAGGATTG
SARS-CoV-2 NC3 Primers	Sequence
NC3 FIP	TGTGTAGGTCAACCACGTTC <i>T</i> <u>GCTTCAGCGTTCTTCGGA</u>
NC3 BIP	GTGCCATCAAATTGGATGACAAAG <u>GTTTTGTATGCGTCAATATGCTTATTCA</u>
	<u>G</u>
NC3 LF + Target adapter	ACCAACACCTCACATCACACATAATATCCATGCCAATGCGCGACA
NC3 LB	CCAAATTTCAAAGATCAAGTCAT
NC3 F3	GACCAGGAACTAATCAGACAAG
NC3 B3	GCTTGAGTTTCATCAGCCTTC
IAC (NC1) primer	Sequence
IAC FL + Control adapter	ACCACACCTACCACCACTAATAACTAACTCCAGCCATCCTCACCATC
SARS-CoV-2 UDP	Sequence
Target (CoV) UDP Probe	FITC-
	CCATCAGCACCAAGACTACCCACCTCGCCACCAA <b>ACCAACACCTCACATCAC</b>
	ΑCΑΤΑΑΤΑ
Target (CoV) UDP Quencher	TTGGTGGCGAGGTGGGTAGTCTTGGTGCTGATGG - Iowa Black® FQ

IAC UDP	Sequence
Control (IAC) UDP Probe	Tex615-
	CCTGACCACTTCCGAACCCAACCACCTACGACAG <b>ACCACACCTACCACCACT</b>
	ΑΑΤΑΑCTAA
Control (IAC) UDP Quencher	CTGTCGTAGGTGGTTGGGTTCGGAAGTGGTCAGG – BHQ®-2
IAC Template	Sequence
IAC ssDNA	AAT GGA CCC CAA AAT CAG CGA AAT GCA CCC CGC ATT ACG TTT GGT
	GGA CCC TCT GGA GTC AAT GGG TGG TGC CAG AAT GGA GAA CGC AGT
	GGG GCG CGA TCA AAA CAA CGT CGG CCC CAA GTT GAT CTC CAG CCA
	TCC TCA CCA TCG TTC ACC GCT CTC ACT CAA CAT GGC AAG AAT TAA
	CAC CAA TAG CAG TCC AGA TG

98

#### 99 Universal displacement probe design

100 Two engineered universal displacement probes (UDP) corresponding to the target adapter or IAC 101 adapter sequence were designed. Each UDP consists of an oligonucleotide duplex with a 3' overhang and a fluorophore quencher pair (19). The adapter sequence is located at the 3' overhang position, with a 102 103 fluorophore spacer sequence at the 5' end and a 5' terminal fluorophore (6-FAM or TEX615). The 104 quencher (Iowa Black® FO or Black hole Quencher®-2) sequence is a complementary fluorophore 105 spacer sequence and is labeled with a 3' dark quencher so that it quenches the fluorophore when annealed. Probe adapters and universal displacement probe sequences were generated from randomized sequence 106 107 and manually modified in Geneious, using OligoAnalyzer and NUPACK as secondary analysis tools, to 108 minimize dimer and hairpin structures within and between the probes and adapted loop primers. All 109 designs were tested individually and multiplexed in combination against synthetic dsDNA gBlocks TM (Integrated DNA Technologies, Coralville, Iowa, USA) target and ssDNA IAC Ultramer TM (Integrated 110 DNA Technologies, Coralville, Iowa, USA) fragments to inform iterative design changes to individual 111 assays. Final design iterations are reported; probes and quenchers oligonucleotides were sourced from 112 113 Interated DNA Technologies (Coralville, Iowa, USA).

# 114 **Patient samples**

A panel of 102 human respiratory specimens was used to evaluate our mLAMP assay

performance. These specimens collected from nasal or nasopharyngeal swabs were suspended in 3mL

- 117 viral transport medium (Becton Dickinson 220220), aliquoted, and stored at -80°C until testing as
- described (20). The panel was originally characterized by OpenArray (ThermoFisher Scientific, Waltham,
- 119 MA, USA) to contain at least 30 COVID-POS across a wide range of concentrations and 30 COVID-
- 120 negative samples as well as other samples identified as positive for other respiratory diseases including,
- but not limited to, *Streptococcus pneumoniae*, Influenza, seasonal Coronavirus, Adenovirus, and
- 122 Enterovirus. **Supplementary Table S1** shows detailed profile in each specimen used in this study.
- Samples were reassessed in house for the presence of SARS-CoV-2 RNA, as described below, to account
- for losses during freeze-thaws, storage, or extraction. In-house results were used as the reference standard.
- 125 Specimens were collected and tested for SARS-CoV-2 infection as part of the Seattle Flu Study, as
- approved by the Institutional Review Board at the University of Washington (IRB#: STUDY0006181).
- 127 Informed consent was obtained for all participant samples, including for use of de-identified, remnant
- specimens.

# 129 Patient sample preparation

Specimens were extracted using the QIAamp Viral RNA Mini Kit (Qiagen # 52906) according to
 the manufacturer's protocol. 100µL of sample was mixed with 40µL negative VTM (to reach the
 manufacturer's recommended 140µL input), extracted, and eluted in 70µL buffer. 5µL aliquots were
 prepared for single use to avoid free thawing and stored at -80°C until use.

### 134 mRTLAMP protocol

135 20μL mRT-LAMP reaction contains 5mM DTT, 8 mM magnesium sulfate, 20 mM Tris-HCl, 10

136 mM ammonium sulfate, 10 mM KCl, 0.5% (v/v) Triton X-100, 1µM of each FIP and BIP primers, 500

nM of each LF and FB primers, 200 nM of each FV and BV primers, 200 nM FAM-tagged UDP probe

and TEX 615 UDP probe, 300 nM Quencher 1 and Quencher 2 probes, 10 units of RNasin® Plus

Ribonuclease Inhibitor (Promega, N2611), 6 units of WarmStart® RTx (NEB, M0380L), 0.7 µg TFpol
 polymerase, and 2 units of thermostable inorganic pyrophosphatase (NEB, M0296L). 5µL of extracted

140 polymerase, and 2 units of memostable morganic pyrophosphatase (NEB, M0290E). SpE of extracted 141 RNA was added to  $15\mu$ L mLAMP reaction mixture and incubated at  $63.3^{\circ}$ C for 1 hour. Fluorescence

142 measurements for FAM and TEX 615 signal, indicating SARS-CoV-2 and IAC amplification,

respectively, were taken every 25 seconds (accounting for 13 second cycle and read times).

# 144 **RT-PCR protocol**

145 The RT-PCR protocol was prepared as previously described (20). Each 20µL RT-PCR reaction

146 contains 5mM DTT, 200µM ea. dNTP, 1x of either N1, N2, or RP primer/probe mix (IDT, 10006770),

147 80mM Tris-sulfate, 20mM ammonium sulfate, 4mM magnesium sulfate, 5% (*v/v*) glycerol, 5% (*v/v*)

148 DMSO, 0.06% (v/v) IGEPAL CA-630, 8.4% (w/v) trehalose, 0.05% (v/v) Tween-20, 0.5% (v/v) Triton X-

149 100, 7.5U reverse transcriptase (NEB M0380L), and 2.5U polymerase (NEB M0481L). 5μL of extracted

150 RNA was added to the  $15\mu$ L RT-PCR reaction mixture and subjected to 5 minutes at 55°C, 1 minutes of

151 94°C and 45 cycles of 1 second 94°C and 30 seconds at 57°C and read using FAM channel on a CFX96

(Bio-Rad Laboratories, Hercules, California). Each clinical sample was run with one technical replicate
 for each N1, N2, or RP assay, along with standards using synthetic RNA templates prepared in-house and

155 for each N1, N2, of RP assay, along with standards using synthetic RNA templates prepared in-nouse and quantified using ddPCR as described (21). Cq and SQ values were exported from Bio-Rad CFX Maestro

155 1.1 software (version 4.1.2433.1219) using the RFU threshold of 50 across all datasets.

# 156 Sequence analysis

157 Genomic sequences of SARS-COV-2 were downloaded from GISAID.ORG

158 (acknowledgements: Supplementary Tables S2-S8). Criteria for inclusion were: sequences with

designation as a Variant of Concern (VOC) or Variant of Interest (VOI) filtered for completeness, high

160 coverage, collection on or before June 14, 2021 and submitted prior to July 1, 2021. The first 1000

sequence records for each VOC / VOI in the GISAID.ORG database were used for subsequent analysis.

- 162 This sequence library was screened for perfect identity matches with the primer binding regions of the
- 163 NC1, NC2, NC3 assays using the packages Biostrings (22) and Seqnir for R (23).

# 164 **Results**

165 To efficiently combine mRT-LAMP assays and differentiate between target and IAC

amplification in a crude sample matrix requires two key features: a target specific probe technology (Fig.

167 1) and a strand displacement polymerase with low non-template amplification. We developed fluorescent

universal displacement probes (**UDP**s) to allow multiplexed assays to be combined or parsed into

169 fluorescence channels with a minimum number of probes. UDPs themselves are engineered sequences

that use a universal adapter sequence on a loop primer for target-specific detection (**Fig. 1A**). In the

171 configuration presented here, three independent SARS-CoV-2 targets are designed to report to a single

- green (6-FAM) fluorescent probe, and the IAC is designed to report to a red (TEX615) fluorescence
- 173 channel (**Fig. 1B**). We previously developed an in-house thermostable strand displacement polymerase
- 174 (TFpol) with very low nonspecific amplification that is amenable to multiplexing. The TFpol design was
- inspired by the chimeric polymerase method of Morant (24) using the poll polymerase of *Thermus*
- 176 *Thermophilus* as the backbone, an enzyme shown to be tolerant of many polymerase inhibitors (25, 26).
- 177 UDPs and TFpol combine to allow for a flexible and robust mLAMP system, compatible with multiple
- target redundancy, IAC controls, and potential for reduced sample preparation.
- 179
- 180

# 181 Figure 1: Multiplexed RT-LAMP (mRT-LAMP) fluorescence detection by Universal Displacement

**Probes (UDP). A)** UDP incorporation during LAMP amplification and activation by displacement of

183 quenching strand. Primer and probe refer to loop (L), adapter (A), and quencher (Q), with complementary

sequences denoted with the suffix "c" (e.g., "Lc" is the reverse complement "L"). **B**) Two-channel

185 fluorescence detection of multiplexed redundant LAMP products (**6-FAM**) and shared-primer IAC

- 186 (TEX615) by UDPs. Primer designations refer to forward (F), backward (B), and loop (L) using
- 187 conventional LAMP terminology.
- 188

# 189 Analytical performance of SARS-CoV-2 mRT-LAMP

Functionality of the individual redundant targets in the mRT-LAMP was verified using synthetic
 RNA fragments corresponding to NC1, NC2, or NC3 mRT-LAMP assay footprints. All three target
 regions generated detectable amplification (Supp. Fig. S1A) with similar average reaction times with 200
 copies of transcript RNA (NC1: 26.4 min, NC2: 26.3, NC3: 28.7 min; Supp. Fig. S1B).

194 The multiplexed assay was evaluated with synthetic target RNA containing all three target 195 regions in the presence of 105 copies of a single-stranded DNA internal amplification control (Fig. 2A). 196 The amount of IAC was chosen to allow detection of low-copy targets prior to detection of the IAC, in 197 order to reduce resource competition between target and control amplifications. This timing differential is 198 possible because of the reduced rate of amplification with a single loop primer in the IAC primer set, 199 when compared to the target assays with a standard complement of LAMP primers. Input of 200 SARS-200 CoV-2 RNA copies (Fig. 2A, top) resulted in detection of green fluorescence in about 21 minutes, while 201 the IAC was not detected. For zero SARS-CoV-2 input copies, there was no target amplification, and the 202 IAC signal was detected by red fluorescence at about 27.5 minutes (Fig. 2A, bot). This behavior is ideal 203 for a shared-primer IAC strategy, permitting detection of the target organism or, alternatively, validating 204 the assay chemistry with the control reaction in the absence of target NAs. The analytical sensitivity was 205 assessed with synthetic RNA target (Fig. 2B). All reactions containing target RNA were positive, and all NTC reactions detected IAC amplification and were negative for target (Fig. 2A). Some IAC 206 207 amplifications were detected in low copy reactions containing target RNA (Fig. 2A), but their presence 208 did not compromise target detection. The assay detected down to 5 copies per reaction (n=4), and all

reactions had threshold times of 30 minutes or less for both the target and IAC (**Fig. 2C**).

- 210
- 211

#### Figure 2: Analytical performance of mRT-LAMP for SARS-CoV-2. A) Characteristic amplification 212

- 213 of multiplexed SARS CoV-2 target and internal amplification control (IAC) with real-time fluorescence
- 214 detection by universal displacement probes (**UDP**). Single representative run with 200 copies of synthetic
- RNA input or a no template control (NTC). B) Analytical sensitivity of multiplexed SARS-CoV-2 target 215
- 216 and IAC. IAC amplifications (bottom) correspond to target amplifications (top). Target synthetic RNA
- 217 input: 2,000 (n=3), 200 (n=3), 20 (n=3), 10 (n=3), or 5 copies per reaction (n=4); and NTC (n=3). C)
- Time to detect signals from SARS-CoV-2 and IAC for reactions from panel **B**. 218
- 219

#### 220 Tolerance to transport media

221 To evaluate the tolerance of the assay to potential media contaminants, a selection of

- 222 commercially available co buffered transport reagents were spiked into reactions with a 25% final
- 223 concentration. For a 20µL total reaction volume, 5µL of 1x DMEM (11965-06, Gibco), 1x VTM (BD
- 224 220527, Copan), 1x PBS (SH30256.01, GE) or 0.9% sodium chloride (diluted from 5M stock 71386-1L,
- 225 Sigma) was added into the mRT-LAMP reactions with final synthetic SARS-CoV-2 RNA of 0, 20, or 200
- copies (Supp. Fig. S2). Successful SARS-COV-2 amplification was observed for all samples containing 226
- 227 template under all buffer conditions.

#### 228 Performance with extracted clinical specimens

- 229 The SARS-CoV-2 mRT-LAMP was evaluated against a collection of pre-extracted patient
- 230 specimens. Of the 102 samples evaluated by RT-PCR, 93 were determined to contain human origin
- 231 material by positive RNase P (**RP**) results; all samples that were negative for RP were also negative for
- 232 SARS-CoV-2 and were considered indeterminate. Of the 93 specimens verified to contain human
- 233 material, 60 were found to be negative for SARS-CoV-2, and 30 were found to be positive by both
- 234 reference RT-RCR assays. The three remaining samples were positive for SARS-CoV-2 by one reference
- 235 RT-PCR assay and negative by the second, resulting in an inconclusive classification. All samples that 236 were indeterminate or inconclusive by RT-PCR were excluded from analysis. Clinical samples were run
- - 237 in duplicate mRT-LAMP reactions.
  - 238 The mRT-LAMP was able to detect negatives with 100% specificity in both sets of replicates,
  - 239 with detection of the IAC but no target signal (Fig. 3). Conversely, sensitivity for the two replicates was
  - 240 90% (27/30) and 87% (26/30), respectively. For samples found to have more than 30 copies / mRT-
  - 241 LAMP reaction by reference RT-PCR, sensitivity was improved to 100% (21/21) for both replicates. The 242
  - OpenArray characterization of the verified samples found 57 of 90 validated samples contained one or 243
  - more other respiratory infections; 8 of 9 SARS-CoV-2 positive samples with coinfections were correctly
  - 244 called as SARS-CoV-2 positive, 48 of 48 SARS-CoV-2 negative samples that were positive for other
  - 245 pathogens were correctly called as SARS-CoV-2 negative.
  - 246
  - 247
  - 248 Figure 3: mRT-LAMP amplification of extracted nasal specimens. Samples confirmed positive or 249 negative for SARS-CoV-2 and positive for the RNase P human marker by RT-PCR panel (N1, N2, RP)
  - were amplified by duplicate mRT-LAMP reactions. Detected mRT-LAMP signals for SARS-CoV-2 250
  - 251 (CoV) are shown in blue, and IAC signals are shown in orange; replicate pairs are connected by a line
  - 252 segment. Mean copy number was derived from qPCR results of N1, N1 PCR (see Supplemental Table
  - 253 **S1**).

#### 254 **Primer coverage analysis**

Individual primer sets had variability in the frequency of perfect primer matches across the

256 VOC/VOI sequence libraries (**Table 2**). Presence of mismatches does not necessarily preclude assay

functionality and is therefore an underestimate of realized assay coverage. Combined primer coverage,

where one or more primer sets had a perfect match for the target, was high across all variants, with a

259 minimum 97.4% (for Eta).

	Primer set (% of perfect primer set alignment to 1000 sequences)				
SARS-COV-2 VOC/VOI	NC1 NC2 Primers Primer		NC3 Primers	multiplex coverage (1+ primer set match)	
Alpha	71.8	90.0	79.9	100.0	
Beta	96.4	90.4	95.9	100.0	
Delta	96.7	96.5	00.0	99.8	
Epsilon	94.6	93.7	81.2	99.6	
Gamma	00.5	80.7	88.6	98.8	
Eta	93.9	00.4	83.7	97.4	
Iota	88.0	81.5	92.5	99.9	

#### 260 Table 2: Coverage of Variant Sequences by individual and multiplexed targets

261

262

263

# 264 **Discussion**

265 This initial validation of a multiplexed reverse transcription LAMP assay is a further step towards more resilient point-of-care NAAT technologies with convenient implementation and development. The 266 assay supports robust but basic functionality with competitive sensitivity, speed, and a low complexity 267 fluorescence detection system. Because VTM has been shown to inhibit conventional PCR strategies (27), 268 269 we designed our assay to use our in-house chimeric polymerase, TFpol, which has been proven to be 270 effective with complex samples containing various transport media. TFpol supports multiplexed LAMP amplifications which have been infrequently demonstrated. These capabilities, taken together, enable 271 272 features that are contemporary in high-throughput laboratory testing but more challenging in point-of 273 care diagnostics.

Multiplexed LAMP reactions with the ability to differentiate individual products by target specific probes enable two key aspects of robust NAAT testing: internal amplification controls and multiple target redundancy. IACs are widely accepted as a means of assuring the sample could detect a positive result if the target result is negative, by verifying that the reaction chemistry was viable and not inhibited by sample contaminants or otherwise compromised (28). In the context of LAMP amplification, internal controls can impair successful target detection; the resource demands of a successful LAMP

mean co-amplification of multiple products with varying inputs often lead to the competitive inhibition of
slower assays or lower concentration of target (Fig. 2B, 2C). Presumably, this can be attributed to
resource depletion of limiting reagents in the reaction mix. To address this resource competition, we
devised a shared-primer internal control strategy where the performance of the IAC has been intentionally
impaired by using a reduced primer set. The delayed time-to-detection of the IAC can then be further
controlled by adjusting the concentration of control template, ensuring reduced competition with the
target amplification.

287 The single-pot multiple target redundancy is a defining feature of this assay design even with the 288 grouped reporter signal. Pathogen genetic variability is an important failure mode for nucleic acid amplification tests; a single nucleotide point mutation (SNP) can result in underperformance of a LAMP 289 290 (29) or PCR reaction (30). As the COVID-19 pandemic progresses, the virus will continue to accumulate 291 mutations and diversify, posing a challenge to NAATs used for diagnosis. An alignment of publicly 292 available SARS-CoV-2 genomes at the time of writing reveals multiple genomes with known mutations 293 in the primer footprints of the CDC PCR designs and a range of other published assays, suggesting that mutations are an existential problem (data not shown). The likelihood of these mutations rendering all 294 295 three target amplifications ineffective simultaneously is lower than for a single assay. This principle is 296 often incorporated in commercially available conventional laboratory based NAATs so this capability 297 represents a convergence of state-of-the-art diagnostic methods and POC diagnostic capabilities. Our own 298 analysis (Fig. 2) found that, since the design of the multiplex assay in early 2020 against the NCBI 299 reference sequence, the emergence of the many variant lineages had resulted in some high frequency 300 mismatches in primer binding regions of our targets. While many single nucleotide polymorphisms are 301 likely to be tolerated by a LAMP reaction, some mutations, such as those located at or near the critical 302 termini of primers, may interfere with diagnostic performance (31). Variants Delta, Gamma and Eta each 303 had fixed, or almost fixed allele mutations in primer sets NC3, NC1, and NC2 respectively. When considered in combination as a multiplex assay, the primers still showed good overall coverage despite 304 305 one of the three assays being potentially compromised; this is a clear demonstration of the value that 306 multitarget redundancy holds for viral diagnostics. In the case of the Delta variant, which currently has 307 rising incidence (32), a sequence mutation within the NC3 primer set was identified on the reverse bumper primer (B3, data not shown). This primer could be altered to be inclusive to the delta variant or 308 309 redesigned without disruption to the diagnostic, ensuring no lapse in diagnostic coverage over time.

310 In order to fully realize a field ready POC assay additional development is planned. While 311 preliminary testing suggests that the system is tolerant to inhibitors that might typically interfere with a 312 direct-to-amplification workflow, in-amplification sample lysis, and testing with human sample matrix 313 will be necessary. This is particularly important for understanding the role of RNAses on assay 314 sensitivity. With the current ssDNA IAC design RNA integrity is not assessed by the control system, 315 which is essential for a fully functional process control. Future iterations will address this by 316 implementing an encapsidated RNA, such as MS2 coliphage for this purpose. Sampling, storage, and 317 portable device solutions are already under development (13). These advancements will allow us to eschew infrastructure requirements that have acted as a bottleneck in current testing efforts, and when 318 319 combined with the robust multiplex chemistry presented here, could act as a practical solution for 320 decentralized testing.

#### 321 Author Contributions

E.K. designed this unique version of LAMP assay and in-house polymerase. E.K., I.T.H., and
 Q.W. prepared the in-house polymerase and synthetic RNA targets. N.P. and E.K. performed mRT-

LAMP experiments. N.P. and A.K.O. performed extraction of clinical specimens, RT-qPCR. E.K.

performed the analysis of mRT-LAMP and RT-qPCR. P.D.H. and L.M.A. designed the specimens panel
 used in this study and characterized these specimens using RT-qPCR and OpenArray. B.R.L. oversaw the

327 study. All authors contributed to writing this manuscript.

#### 328 Acknowledgments

329 We thank other project members in the Lutz lab for their feedback: Robert Atkinson, Michael 330 Roller, Crissa Bennett, Daniel Lyon, and Jack Henry Kotnik. We thank Dr. Syamal Raychaudhuri, Dr. Frances Chu from Inbios International, and Dr. Gwong-Jen J. Chang for stimulating discussion. We thank 331 the Seattle Flu Study and the Seattle Coronavirus Assessment Network (SCAN) teams led by Principal 332 333 Investigators: Helen Y. Chu, MD, MPH, Michael Boeckh, MD, PhD, Janet A. Englund, MD, Michael 334 Famulare, PhD, Barry R. Lutz, PhD, Deborah A. Nickerson, PhD, Mark J. Rieder, PhD, Lea M. Starita, 335 PhD, Matthew Thompson, MD, MPH, DPhil, Jay Shendure, MD, PhD and Trevor Bedford, PhD for 336 providing specimens for testing. This work was supported by the Seattle Flu Study (funded by Gates 337 Ventures) and the National Institutes of Health (R01AI140845; 5R61AI140460-03). I.T.H. was supported in part by the National Institute of General Medical Sciences of the National Institutes of Health under 338 339 Award Number T32GM008268. This work does not reflect the views of the funders. The funders were 340 not involved in the design of the study, and funders do not have any ownership over the management and

341 conduct of the study, the data, or the rights to publish.

#### 342 Conflicts of Interest

- Patent applications have been filed on several components of this assay. E.C.K., N.P., Q.W.,
- 344 I.T.H., D.L. and B.R.L. are inventors on one or more provisional patent applications. E.C.K., N.P., Q.W.,
- I.T.H., A.K.O, and B.R.L. have equity in a startup company that licenses this technology.

#### 346 **References**

- Ghebreyesus TA. 2020. WHO Director-General's opening remarks at the media briefing on
   COVID-19 11 March 2020.
- Centers for Disease Control and Prevention. 2021. CDC Strategy for Global Response to COVID-19 (2020-2023).
- Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, Plessis L du, Pybus OG. 2020.
   A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology.
   Nat Microbiol 5:1407.
- United States Food and Drug Administration. 2021. Genetic Variants of SARS-CoV-2 May Lead
   to False Negative Results with Molecular Tests for Detection of SARS-CoV-2 Letter to Clinical
   Laboratory Staff and Health Care Providers.
- Stellrecht KA. 2018. The Drift in Molecular Testing for Influenza: Mutations Affecting Assay
   Performance. J Clin Microbiol 56:e01531-17.
- Ison CA, Golparian D, Saunders P, Chisholm S, Unemo M. 2013. Evolution of Neisseria
  gonorrhoeae is a continuing challenge for molecular detection of gonorrhoea: false negative
  gonococcal porA mutants are spreading internationally. Sex Transm Infect 89:197–201.
- Peñarrubia L, Ruiz M, Porco R, Rao SN, Juanola-Falgarona M, Manissero D, López-Fontanals
   M, Pareja J. 2020. Multiple assays in a real-time RT-PCR SARS-CoV-2 panel can mitigate the

364 365		risk of loss of sensitivity by new genomic variants during the COVID-19 outbreak. Int J Infect Dis 97:229.
366 367	8.	World Health Organization. 2021. WHO information for the molecular detection of influenza viruses.
368 369	9.	Obande GA, Singh KKB. 2020. Current and Future Perspectives on Isothermal Nucleic Acid Amplification Technologies for Diagnosing Infections. Infect Drug Resist 13:483.
370 371	10.	Tanner NA, Zhang Y, Evans TCJ. 2012. Simultaneous multiple target detection in real-time loop- mediated isothermal amplification. Biotechniques 53:81–89.
372 373 374	11.	Ding S, Chen G, Wei Y, Dong J, Du F, Cui X, Huang X, Tang Z. 2021. Sequence-specific and multiplex detection of COVID-19 virus (SARS-CoV-2) using proofreading enzyme-mediated probe cleavage coupled with isothermal amplification. Biosens Bioelectron 178:113041.
375 376	12.	Bhadra S, Riedel TE, Lakhotia S, Tran ND, Ellington AD. 2021. High-Surety Isothermal Amplification and Detection of SARS-CoV-2. mSphere 6:e00911–e00920.
377 378 379 380	13.	Panpradist N, Kline E, Atkinson RG, Roller M, Wang Q, Hull IT, Kotnik JH, Oreskovic AK, Bennett C, Leon D, Lyon V, Gilligan-Steinberg S, Han PD, Drain PK, Starita LM, Thompson MJ, Lutz BR. 2021. Harmony COVID-19: a ready-to-use kit, low-cost detector, and smartphone app for point-of-care SARS-CoV-2 RNA detection. medRxiv.
381 382	14.	Rozen S, Skaletsky H. 2000. Primer3 on the WWW for General Users and for Biologist Programmers. Methods Mol Biol 132:365–386.
383	15.	Integrated DNA Technologies. 2020. OligoAnalyzerTM Tool. Coralville, Iowa.
384 385	16.	Zadeh JN, Steenberg CD, Bois JS, Wolfe BR, Pierce MB, Khan AR, Dirks RM, Pierce NA. 2011. NUPACK: Analysis and design of nucleic acid systems. J Comput Chem 32:170–173.
386 387	17.	Nagamine K, Hase T, Notomi T. 2002. Accelerated reaction by loop-mediated isothermal amplification using loop primers. Mol Cell Probes 16:223–229.
388 389 390	18.	Hoorfar J, Malorny B, Abdulmawjood A, Cook N, Wagner M, Fach P. 2004. Practical Considerations in Design of Internal Amplification Controls for Diagnostic PCR Assays. J Clin Microbiol 42:1863–1868.
391 392 393	19.	Faltin B, Zengerle R, von Stetten F. 2013. Current Methods for Fluorescence-Based Universal Sequence-Dependent Detection of Nucleic Acids in Homogenous Assays and Clinical Applications. Clin Chem 59:1567–1582.
394 395 396	20.	Panpradist N, Wang Q, Ruth PS, Kotnik JH, Oreskovic AK, Miller A, Stewart SWA, Vrana J, Han PD, Beck IA, Starita LM, Frenkel LM, Lutz BR. 2021. Simpler and faster Covid-19 testing: Strategies to streamline SARS-CoV-2 molecular assays. EBioMedicine 64:103236.
397 398 399	21.	Gulati GK, Panpradist N, Stewart SW, Beck IA, Boyce C, Oreskovic AK, Avila-Ríos S, Han PD, Reyes-Terán G, Starita L, Frenkel LM, Lutz BR, Lai JJ. 2021. Inexpensive workflow to enable simultaneous monitoring HIV viral load and detection of SARS-CoV-2 infection. medRxiv.
400 401	22.	Pagès H, Aboyoun P, Gentleman R, DebRoy S. 2021. Biostrings: Efficient manipulation of biological strings. 2.60.2. Bioconductor.

402 403 404 405	23.	Charif D, Lobry JR. 2007. SeqinR 1.0-2: A Contributed Package to the R Project for Statistical Computing Devoted to Biological Sequences Retrieval and Analysis, p. 207–232. In Bastolla, U, Porto, M, Roman, H, Vendruscolo, M (eds.), Structural Approaches to Sequence Evolution. Springer, Berlin, Heidelberg.
406 407	24.	Morant N. 2015. Novel thermostable DNA Polymerases for isothermal DNA amplification. University of Bath, Bath, United Kingdom.
408 409	25.	Poddar S, Sawyer M, Connor J. 1998. Effect of Inhibitors in Clinical Specimens on Taq and Tth Dna Polymerase-Based Pcr Amplification of Influenza A Virus. J Med Microbiol 47:1131–1135.
410 411 412	26.	Abu Al-Soud W, Rådström P. 1998. Capacity of nine thermostable DNA polymerases to mediate DNA amplification in the presence of PCR-inhibiting samples. Appl Environ Microbiol 64:3748–3753.
413 414	27.	Kirkland P, Frost M. 2020. The impact of viral transport media on PCR assay results for the detection of nucleic acid from SARS-CoV-2. Pathology 52:811–814.
415 416 417	28.	Hoorfar J, Cook N, Malorny B, Wagner M, De Medici D, Abdulmawjood A, Fach P. 2003. Making Internal Amplification Control Mandatory for Diagnostic PCR. J Clin Microbiol 41:5835.
418 419	29.	Wang D. 2016. Effect of internal primer-template mismatches on loop-mediated isothermal amplification. Biotechnol Biotechnol Equip 30:314–318.
420 421 422	30.	Ayyadevara S, Thaden JJ, Shmookler Reis RJ. 2000. Discrimination of Primer 3'-Nucleotide Mismatch by Taq DNA Polymerase during Polymerase Chain Reaction. Anal Biochem 284:11–18.
423 424	31.	Li Y, Zhou Y, Ma Y, Xu R, Jin X, Zhang C. 2019. A Mismatch-tolerant RT-LAMP Method for Molecular Diagnosis of Highly Variable Viruses. Bio-protocol 9:e3415.
425	32.	GISAID. 2021. Tracking of Variants.
426		





